Human monoclonal antibodies against amyloid-beta from healthy adults

被引:50
作者
Geylis, V
Kourilov, V
Meiner, Z
Nennesmo, I
Bogdanovic, N
Steinitz, M
机构
[1] Hebrew Univ Jerusalem, Hadassah Med Sch, IL-91120 Jerusalem, Israel
[2] Hadassah Univ Hosp, Dept Neurol, IL-91120 Jerusalem, Israel
[3] Huddinge Univ Hosp, Dept Pathol, S-14186 Huddinge, Sweden
[4] Karolinska Inst, Dept Geriatr Med, S-14186 Huddinge, Sweden
关键词
Alzheimer's disease; anti-amyloid-beta antibodies; Epstein-Barr virus; human monoclonal antibodies; immunotherapy; passive immunization;
D O I
10.1016/j.neurobiolaging.2004.06.008
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Two anti-amyloid-beta human antibody-producing cell lines were established from amyloid-beta (Abeta)-selected lymphocytes from peripheral blood of healthy adults. ELISA and Western blot analysis showed that the monoclonal antibodies bound with high affinity to the 43 amino acid-long amyloid-beta peptide. The antigen epitope of these antibodies encountered within amino acids 1-16 of the amyloid-beta peptide. The antibodies did not bind to several immunoglobulin light chain amyloids (AL) and amylin. One of the monoclonals was tested by immunohistochemistry for the binding to frozen sections of brains derived from patients with Alzheimer's disease. It specifically and intensively stained diffuse and core amyloid-beta plaques; whereas, sections from normal brains were not stained. Concomitant staining with a commercial mouse anti-amyloid-beta monoclonal antibody co-localized with that of the human antibody. Simultaneous staining with the human antibody and Congo red implied that the antibody binds primarily to an early immature form of beta-amyloid. Human monoclonal antibodies, which resemble physiologically normal non-pathogenic and possibly protective antibodies in healthy adults, might be attractive candidates for immune therapy of Alzheimer's disease. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:597 / 606
页数:10
相关论文
共 47 条
[1]   Inflammation and Alzheimer's disease [J].
Akiyama, H ;
Barger, S ;
Barnum, S ;
Bradt, B ;
Bauer, J ;
Cole, GM ;
Cooper, NR ;
Eikelenboom, P ;
Emmerling, M ;
Fiebich, BL ;
Finch, CE ;
Frautschy, S ;
Griffin, WST ;
Hampel, H ;
Hull, M ;
Landreth, G ;
Lue, LF ;
Mrak, R ;
Mackenzie, IR ;
McGeer, PL ;
O'Banion, MK ;
Pachter, J ;
Pasinetti, G ;
Plata-Salaman, C ;
Rogers, J ;
Rydel, R ;
Shen, Y ;
Streit, W ;
Strohmeyer, R ;
Tooyoma, I ;
Van Muiswinkel, FL ;
Veerhuis, R ;
Walker, D ;
Webster, S ;
Wegrzyniak, B ;
Wenk, G ;
Wyss-Coray, T .
NEUROBIOLOGY OF AGING, 2000, 21 (03) :383-421
[2]  
AVRAMEAS S, 1991, IMMUNOL TODAY, V12, P154
[3]   Imaging of amyloid-β deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy [J].
Backskai, BJ ;
Kajdasz, ST ;
Christie, RH ;
Carter, C ;
Games, D ;
Seubert, P ;
Schenk, D ;
Hyman, BT .
NATURE MEDICINE, 2001, 7 (03) :369-372
[4]   Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease [J].
Bard, F ;
Cannon, C ;
Barbour, R ;
Burke, RL ;
Games, D ;
Grajeda, H ;
Guido, T ;
Hu, K ;
Huang, JP ;
Johnson-Wood, K ;
Khan, K ;
Kholodenko, D ;
Lee, M ;
Lieberburg, I ;
Motter, R ;
Nguyen, M ;
Soriano, F ;
Vasquez, N ;
Weiss, K ;
Welch, B ;
Seubert, P ;
Schenk, D ;
Yednock, T .
NATURE MEDICINE, 2000, 6 (08) :916-919
[5]   Epitope and isotype specificities of antibodies to β-amyloid peptide for protection against Alzheimer's disease-like neuropathology [J].
Bard, F ;
Barbour, R ;
Cannon, C ;
Carretto, R ;
Fox, M ;
Games, D ;
Guido, T ;
Hoenow, K ;
Hu, K ;
Johnson-Wood, K ;
Khan, K ;
Kholodenko, D ;
Lee, C ;
Lee, M ;
Motter, R ;
Nguyen, M ;
Reed, A ;
Schenk, D ;
Tang, P ;
Vasquez, N ;
Seubert, P ;
Yednock, T .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (04) :2023-2028
[6]  
Bogdanovic N, 1995, BIOMEDICAL HLTH RES, P20
[7]   A learning deficit related to age and β-amyloid plaques in a mouse model of Alzheimer's disease [J].
Chen, GQ ;
Chen, KS ;
Knox, J ;
Inglis, J ;
Bernard, A ;
Martin, SJ ;
Justice, A ;
McConlogue, L ;
Games, D ;
Freedman, SB ;
Morris, RGM .
NATURE, 2000, 408 (6815) :975-979
[8]   Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease [J].
DeMattos, RB ;
Bales, KR ;
Cummins, DJ ;
Dodart, JC ;
Paul, SM ;
Holtzman, DM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (15) :8850-8855
[9]   Brain to plasma amyloid-β efflux:: a measure of brain amyloid burden in a mouse model of Alzheimer's disease [J].
DeMattos, RB ;
Bales, KR ;
Cummins, DJ ;
Paul, SM ;
Holtzman, DM .
SCIENCE, 2002, 295 (5563) :2264-2267
[10]   Human antibodies against amyloid β peptide:: A potential treatment for Alzheimer's disease [J].
Dodel, R ;
Hampel, H ;
Depboylu, C ;
Lin, SZ ;
Gao, F ;
Shock, S ;
Jäckel, S ;
Wei, W ;
Buerger, K ;
Höft, C ;
Hemmer, B ;
Möller, HJ ;
Farlow, M ;
Oertel, WH ;
Sommer, N ;
Du, YS .
ANNALS OF NEUROLOGY, 2002, 52 (02) :253-256